Charles River extends Huntington’s Disease collaboration, shutters site in San Diego

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Radachynskyi)
(Image: Getty/Radachynskyi)

Related tags: Charles river laboratories

Charles River Laboratories has extended its ongoing collaboration with the CHDI Foundation by five-years – and is closing its San Diego, CA-based research model production facility.

Charles River Laboratories​ and the CHDI Foundation have been collaborating on drug discovery and development for Huntington’s disease (HD) since 2005.

Over the course of the 14-year relationship, the companies have identified novel potential drug targets, bred and validated translational research animal models, and generated proof-of-concept molecules.

The companies also have evaluated the potential efficacy of both small molecule and biologic candidates in preclinical models of HD, a genetic neurological disease that causes the progressive dysfunction of nerve cells in the brain.

Under the extended contract, Charles River will provide various services, including complex primary neuronal assay development, high-content and fragment-based screening, absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetics (PK), among others.

Streamlining operations

Also earlier this month, Charles River announced plans to close its research model production facility in San Diego, CA, which currently employs 24 people. A company spokesperson told us in a statement:

“As part of our continuing efforts to streamline operations and enhance efficiencies, we have made the decision to close our research model production facility in San Diego and relocate all services and production to our Hollister site.

“Charles River is committed to maintaining its world-class client service and will ensure that the site closure will not impact availability or service.”

The permanent closure will be effective May 20, 2019, per the WARN notice.

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars